Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.01-0.25 (-2.44%)
At close: 04:00PM EDT
10.03 +0.02 (+0.20%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.26
Open10.87
Bid9.96 x 500
Ask10.02 x 1800
Day's range9.85 - 10.88
52-week range3.21 - 18.33
Volume6,429,602
Avg. volume6,447,187
Market cap2.801B
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-1.81
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.92
  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences and Events

    SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Invest

  • Zacks

    Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

    Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

    Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral PresentationStrongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 2